Upgrade Now

Company Announcements

Notice of half year results

Related Companies

By LSE RNS

RNS Number : 0771X
Abzena PLC
21 November 2017
 

Abzena plc

 

Notice of half year results

 

Cambridge, UK, 21 November 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, will publish its half year results for the six months to 30 September 2017 on Tuesday, 12 December 2017.

 

A presentation for analysts will be held at 09:30am on 12 December 2017 at the offices of Instinctif Partners, 65 Gresham Street, London EC2V 7NQ.    

 

-Ends-

 

Enquiries:

 

Abzena plc

John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer

 

+44 1223 903498

Numis (Nominated Adviser and Broker)

Clare Terlouw / James Black / Paul Gillam

 

+44 20 7260 1000

N+1 Singer (Joint Broker)

Aubrey Powell / Liz Yong

 

+44 20 7496 3000

Instinctif Partners

Melanie Toyne Sewell / Alex Shaw / Deborah Bell

 

+44 20 7457 2020

abzena@instinctif.com

 

 

About Abzena


Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

·      Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

·      Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

·      Cell line development for the manufacture of recombinant proteins and antibodies;

·      Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

·      Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

·      Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

·      GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please see www.abzena.com


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORMMMZMRMDGNZG

Top of Page